Martin Hoenigl1,2, John Lin3,4, Malcolm Finkelman5, Yonglong Zhang5, Maile Y Karris1, Scott L Letendre1, Ronald J Ellis6, Leah Burke1, Byron Richard7, Thaidra Gaufin1, Stéphane Isnard3,4, Jean-Pierre Routy3,4, Sara Gianella1. 1. Division of Infectious Diseases and Global Public Health, Department of Medicine, University of California San Diego, San Diego, CA, USA. 2. Section of Infectious Diseases and Tropical Medicine, Medical University of Graz, Graz, Austria. 3. Chronic Viral Illness Service, McGill University Health Centre, Montreal, QC, Canada. 4. Infectious Diseases and Immunity in Global Health Program, Research Institute of McGill University Health Centre, Montreal, QC, Canada. 5. Clinical Development, Associates of Cape Cod, Inc, Falmouth, MA, USA. 6. Department of Neurosciences, University of California San Diego, San Diego, CA, USA. 7. Nutritional Services, University of California San Diego, San Diego, CA, USA.
Abstract
BACKGROUND: (1-3)-b-D-glucan (BDG) is a fungal cell wall component and, in the absence of invasive fungal infection, a novel biomarker for microbial translocation of endogenous fungal products from the gastrointestinal tract into systemic circulation. However, its value as a marker of fungal translocation is limited by a concern that plant BDG-rich food influences blood BDG levels. METHODS: We conducted a pilot clinical trial to evaluate the impact of a standardised oral BDG challenge on blood BDG levels in participants with and without elevated microbial translocation. We enrolled 14 participants including 8 with HIV infection, 2 with advanced liver cirrhosis, and 4 healthy controls. After obtaining a baseline blood sample, participants received a standardised milkshake containing high levels of BDG followed by serial blood samples up to 8 hours after intake. RESULTS: The standardised oral BDG challenge approach did not change the blood BDG levels over time in all participants. We found consistently elevated blood BDG levels in one participant with advanced liver cirrhosis and a single person with HIV with a low CD4 count of 201 cells/mm3 . CONCLUSION: Our findings indicate that BDG blood levels were not influenced by plant origin BDG-rich nutrition in PWH, people with advanced liver cirrhosis, or healthy controls. Future studies are needed to analyse gut mycobiota populations in individuals with elevated blood BDG levels.
BACKGROUND: (1-3)-b-D-glucan (BDG) is a fungal cell wall component and, in the absence of invasive fungal infection, a novel biomarker for microbial translocation of endogenous fungal products from the gastrointestinal tract into systemic circulation. However, its value as a marker of fungal translocation is limited by a concern that plant BDG-rich food influences blood BDG levels. METHODS: We conducted a pilot clinical trial to evaluate the impact of a standardised oral BDG challenge on blood BDG levels in participants with and without elevated microbial translocation. We enrolled 14 participants including 8 with HIV infection, 2 with advanced liver cirrhosis, and 4 healthy controls. After obtaining a baseline blood sample, participants received a standardised milkshake containing high levels of BDG followed by serial blood samples up to 8 hours after intake. RESULTS: The standardised oral BDG challenge approach did not change the blood BDG levels over time in all participants. We found consistently elevated blood BDG levels in one participant with advanced liver cirrhosis and a single person with HIV with a low CD4 count of 201 cells/mm3 . CONCLUSION: Our findings indicate that BDG blood levels were not influenced by plant origin BDG-rich nutrition in PWH, people with advanced liver cirrhosis, or healthy controls. Future studies are needed to analyse gut mycobiota populations in individuals with elevated blood BDG levels.
Authors: Patrice D Cani; Jacques Amar; Miguel Angel Iglesias; Marjorie Poggi; Claude Knauf; Delphine Bastelica; Audrey M Neyrinck; Francesca Fava; Kieran M Tuohy; Chantal Chabo; Aurélie Waget; Evelyne Delmée; Béatrice Cousin; Thierry Sulpice; Bernard Chamontin; Jean Ferrières; Jean-François Tanti; Glenn R Gibson; Louis Casteilla; Nathalie M Delzenne; Marie Christine Alessi; Rémy Burcelin Journal: Diabetes Date: 2007-04-24 Impact factor: 9.461
Authors: Elitza S Theel; Deborah J Jespersen; Seher Iqbal; Jean E Bestrom; Leonard O Rollins; Lori J Misner; Barbara J Markley; Jayawant Mandrekar; Larry M Baddour; Andrew H Limper; Nancy L Wengenack; Matthew J Binnicker Journal: Mycopathologia Date: 2012-09-01 Impact factor: 2.574
Authors: Martin Hoenigl; Michelli Faria de Oliveira; Josué Pérez-Santiago; Yonglong Zhang; Sheldon Morris; Allen J McCutchan; Malcolm Finkelman; Thomas D Marcotte; Ronald J Ellis; Sara Gianella Journal: Medicine (Baltimore) Date: 2016-03 Impact factor: 1.889
Authors: Alexander Szyszkowitz; Christoph Zurl; Anna Herzeg; Anton Berger; Geza Gemes; Martin Mitteregger; Florian Prüller; Juergen Prattes; Ines Zollner-Schwetz; Thomas Valentin; Martin Hoenigl; Robert Krause Journal: Open Forum Infect Dis Date: 2018-11-08 Impact factor: 3.835
Authors: Sahera Dirajlal-Fargo; Carlee Moser; Katherine Rodriguez; Vanessa El-Kamari; Nicholas T Funderburg; Emily Bowman; Todd T Brown; Peter W Hunt; Judith Currier; Grace A McComsey Journal: Open Forum Infect Dis Date: 2019-11-11 Impact factor: 3.835